Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06393712 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Study acronym: cAPPricorn-1
StatusActive, Not Recruiting
PhasePhase 2
Started2024-05-17
View on ClinicalTrials.gov ↗

Amendment history

2026-09-02
Study Status, Study Design, Contacts/Locations v26
Trial sites expanded: 44 → 57 locations
Enrollment closed, study ongoing
Trial sites reduced: 57 → 44 locations
Enrollment targetestimated 200→confirmed 210
2026-07-14
3 amendments v23-v25
3 re-verifications since 2026-05-12, no change to tracked fields
2026-04-23
Study Status, Contacts/Locations v22
Study sitesdetails revised at 36 of 57 sites
2026-03-30
Study Status v21
Re-verified, no change to tracked fields
2026-02-19
Study Status, Contacts/Locations v20
Primary completion date2027-07-01→2027-08-09
Completion date2029-11-01→2029-12-14
Study sites42→57
Show 19 earlier versions
2025-12-18
Study Status, Contacts/Locations v19
Study sites51→42
2025-11-12
Study Status, Contacts/Locations v18
Study sites49→51
2025-11-08
Study Status, Contacts/Locations v17
Study sitescontacts updated at 1 of 49 sites
2025-10-15
Study Status, Contacts/Locations v16
Study sites47→49
2025-09-16
Study Status, Contacts/Locations v15
Study sites44→47
2025-08-27
Study Status, Contacts/Locations, IPDSharing v14
Study sites39→44
2025-07-15
2 amendments v12-v13
2 re-verifications since 2025-06-16, no change to tracked fields
2025-05-12
Study Status, Contacts/Locations v11
Study sites36→39
2025-04-15
Study Status, Contacts/Locations v10
Study sites20→36
2025-03-21
Study Status, Contacts/Locations v9
Study sites13→20
2024-12-04
Study Status, Contacts/Locations v8
Study sites9→13
2024-11-07
Study Status v7
Re-verified, no change to tracked fields
2024-10-11
Study Status, Contacts/Locations v6
Study sites5→9
2024-09-06
Study Status, Contacts/Locations v5
Study sites4→5
2024-08-07
Study Status, Contacts/Locations v4
Study sites2→4
2024-07-18
Study Status, Contacts/Locations v3
Primary completion date2027-07→2027-07-01
Completion date2029-11→2029-11-01
Study sites1→2
2024-06-24
Study Status v2
Start dateestimated 2024-05→confirmed 2024-05-17
2024-05-09
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start date2024-04→2024-05
Study sites0→1
2024-04-26
Original filing
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
Trial Details
NCT Number NCT06393712
Lead Sponsor Alnylam Pharmaceuticals
Conditions Cerebral Amyloid Angiopathy
Enrollment 210 participants
Start Date 2024-05-17
Primary Completion 2027-08-09 (estimated)
Study Completion 2029-12-14 (estimated)
Updated on ClinicalTrials.gov 2026-09-18